Cooper, Jacie T.
Lloyd, Andrew http://orcid.org/0000-0002-7597-6556
Sanchez, Juan Jose Garcia http://orcid.org/0000-0001-6546-7769
Sörstadius, Elisabeth
Briggs, Andrew
McFarlane, Phil
Funding for this research was provided by:
AstraZeneca
Article History
Received: 11 May 2020
Accepted: 9 September 2020
First Online: 21 September 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: The study was funded by AstraZeneca plc. Support for third-party writing assistance, provided by Acaster Lloyd Consulting Ltd., was funded by AstraZeneca plc in accordance with Good Publication Practice (GPP3) guidelines. Disclosures for all authors are as follows:• AL: Employee of Acaster Lloyd Consulting• JC, AB: Employees of Avalon Health Economics• JJGS, ES: Employees of AstraZeneca• PM: Consultancy and research support from AMGEN, Astra-Zeneca, Bayer, Boehringer Ingelheim, Ilanga, Janssen, Lilly, Novartis, Otsuka, Pfizer, Sanofi-Aventis, and Takeda, as well as research support from AMGEN, Astra-Zeneca, Bayer, Boehringer Ingelheim, GSK, Janssen, Novartis, Novo-Nordisk, Ortho-Biotech, Otsuka, and Reata.